RxDoctor Payments Data

Rebecca Runge, DO

Family Medicine · Richland, MINPI 1235421223

Payments from drug & device makers

$706in general payments, 2019–2025

Across 21 payments — averaging $33.64 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Abbott$154
  • Boehringer Ingelheim$145
  • AstraZeneca$77
  • Pfizer$66
  • Novo Nordisk$62
  • Amgen$50
  • plus $152 from 7 others

What the payments were for

  • Food & beverage$706100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
23
24

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$706 in reported general payments places this provider in the 65th percentile of 3,945 family medicine providers in Michigan.

See all family medicine providers in Michigan

Medicare billing

Part B allowed, 2024
$29,183
Medicare patients
134
Services billed
313

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
TrulicityDulaglutide53$69,156
OzempicSemaglutide39$68,950
EliquisApixaban66$62,453
MounjaroTirzepatide34$46,202
Trelegy ElliptaFluticasone/Umeclidin/Vilanter34$34,925
JardianceEmpagliflozin32$32,334
FarxigaDapagliflozin Propanediol24$26,403
MyrbetriqMirabegron22$15,020
NexiumEsomeprazole Magnesium11$7,202
Fluticasone-SalmeterolFluticasone Propion/Salmeterol21$5,632
Rosuvastatin Calcium261$4,719
Levothyroxine Sodium291$3,939
Atorvastatin Calcium254$3,714
Omeprazole165$3,164
Metoprolol Succinate157$2,840

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Lilly USA, LLCTrulicity, Mounjaro$15$115,35887 claims
Novo NordiskOzempic$62$68,95039 claims
PfizerEliquis$66$62,45366 claims
GSKTrelegy Ellipta$14$34,92534 claims
AstraZenecaFarxiga, Nexium$77$33,60535 claims
Boehringer IngelheimJardiance$145$32,33432 claims
AbbVieSynthroid$25$1,49415 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 65th percentile of 3,945 family medicine providers in Michigan.

Other family medicine in Richland

See the full list for Michigan

Where these figures come from

Is this you, or does something look wrong? →